U.S. markets closed

MJardin Group, Inc. (MJARF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0726-0.0019 (-2.55%)
At close: 3:36PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0745
Open0.0630
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0630 - 0.0783
52 Week Range0.0300 - 0.2200
Volume91,570
Avg. Volume164,066
Market Cap6.428M
Beta (5Y Monthly)-0.77
PE Ratio (TTM)N/A
EPS (TTM)-2.1190
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • MJardin Group Completes its First Shipment of Recreational Cannabis to the Province of Alberta
    GlobeNewswire

    MJardin Group Completes its First Shipment of Recreational Cannabis to the Province of Alberta

    TORONTO, March 29, 2021 (GLOBE NEWSWIRE) -- MJardin Group, Inc. (CSE: MJAR) (the “Company” or “MJardin”), a leader in premium cannabis production, today announced that it has made its first shipment of recreational cannabis to the province of Alberta. The initial shipment includes Flint & Embers Hyperion, MJardin’s unique take on the GSC x Conspiracy Kush cultivar, Flint & Embers Orion, MJardin’s unique take on the Whiteberry cultivar, BLLRDR Afghani Bullrider and BLLRDR Wedding Cake. Alberta has been able to transition to the legal cannabis market at an accelerated rate. With nearly half the legal cannabis stores in the country, Alberta has captured the second-highest sales of legal cannabis in Canada (Statistics Canada, 2021), overtaking British Columbia, and second only to Ontario. Alberta hosts the largest proportion of experienced cannabis users, shifting customer expectation towards mature product propositions, forcing cannabis brands to get on board with broader trends in consumer-packaged goods (CPG). Certain trends, along with strategic innovation and portfolio optimization, have helped brands stand out in this evolving province. MJardin’s agile customer-centric strategy has built the framework for success in Alberta. The Company’s Canadian consumer-facing brand, Flint & Embers, and partner brand BLLRDR, launch into Alberta with two distinct brand offerings. The strategy allows The Company freedom and flexibility to flesh out each individual brand resulting in a greater ability to define unique target audiences, develop new products that incorporate features and benefits that reflect customer needs, and fulfil the brands deeper purpose and vision. With unique brand offerings, MJardin’s customer focused strategy continues to broaden their demographic reach across Canada. “We are delighted that our cannabis brands will now be available to consumers in the province of Alberta – Canada’s second largest recreational cannabis market,” stated MJardin Group CEO, Pat Witcher. “Across Canada we are seeing customers migrate from the black market to the legal market, and as competitors come into the market, we continue to re-evaluate our offering to ensure we are exceeding industry expectations.” About MJardin Group MJardin Groups’ mission is to set the standard for successful ownership of assets in the cannabis industry. Our founders spent a decade refining cultivation methodology, collecting and implementing data driven standards and designing state\ of the art facilities. Today, MJardin Group owns multiple operations in Canada, supplying the market with premium products. We are committed to our Canadian First Nation joint ventures and all our strategic partnerships across the cannabis supply chain. MJardin Group is publicly listed on the CSE (MJAR) and headquartered in Toronto, Ontario and Denver, Colorado. The CSE has not in any way passed upon the merits of and has neither approved nor disapproved the contents of this news release. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. Forward-Looking Information This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as, may’, ‘will’, ‘should’, ‘could’, ‘would’, ‘expects’, ‘intends’, ‘plans’, ‘anticipates’, ‘believes’, ‘estimates’, ‘projects’, ‘predicts’, ‘potential’, ‘outlook’ or ‘continue’ or the negative of those forms or other comparable terms. Statements about, among other things, future developments in the business and operations of MJardin Group, contain forward-looking information. These statements should not be read as guarantees of future performance or results. The Company’s forward-looking information and forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information and forward-looking statements, including but not limited to: our ability to identify and pursue growth, financing and other strategic objectives, and the regulatory and economic environments in the jurisdictions we operate or intend to operate or invest in. Reference should also be made to the risks and uncertainties which are discussed in greater detail in the “Risk Factors” section of the Company’s Annual Management’s Discussion and Analysis filed on SEDAR and as described from time to time in documents filed by the Company with Canadian securities regulatory authorities. Readers are cautioned that the foregoing list of factors is not exhaustive. Although such statements are based on management’s reasonable assumptions at the date such statements are made, there can be no assurance that any proposed transactions will occur or that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward-looking information and forward-looking statements. Accordingly, readers should not place undue reliance on the forward-looking information and forward-looking statements. No assurances are given as to the future trading price or trading volumes of MJardin Group’s shares, nor as to the Company’s financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company’s forward-looking information and forward-looking statements contained herein, whether as a result of new information, any future event or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise. MJardin Group assumes no responsibility to update or revise forward-looking information and forward-looking statements to reflect new events or circumstances unless required by applicable law. Caution Regarding Cannabis Operations in the United States Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. Cannabis remains a Schedule I drug under the US Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute or possess cannabis in the United States. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable US federal money laundering legislation. While the approach to enforcement of such laws by the federal government in the United States has trended toward non-enforcement against individuals and businesses that comply with medical or adult-use cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve the Company of liability under US federal law, nor will it provide a defense to any federal proceeding which may be brought against the Company. The enforcement of federal laws in the United States is a significant risk to the business of the Company and any proceedings brought against the Company thereunder may adversely affect the Company’s operations and financial performance. Investor Contact Ali Mahdavi Director of Capital Markets & Investor Relationsali.mahdavi@mjardin.com +1.416.962.3300 Pat Witcher Chief Executive Officerpat.witcher@mjardin.com +1.720.613.4019 Media Contact Terra Kimery Director of Marketing & Brand terra.kimery@mjardin.com Related Links www.mjardin.com www.flintandembers.com

  • Spectral Medical Announces the Appointment of Chris Seto to CEO
    GlobeNewswire

    Spectral Medical Announces the Appointment of Chris Seto to CEO

    Dr. Paul Walker will remain on the Board of Directors focusing on the seamless transition of management and on ensuring continuity of the Tigris Trial TORONTO, March 08, 2021 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today announced the appointment of Chris Seto to Chief Executive Officer (“CEO”), effective April 1, 2021. In his new role, Mr. Seto will continue to serve as the Company’s Chief Financial Officer (“CFO”). Dr. Paul Walker, current CEO, will remain committed to the Company as a member of the Board of Directors, where he will be responsible for a seamless transition of leadership, and focus his efforts on the Tigris Trial supporting Dr. John Kellum, Spectral’s recently announced Chief Medical Officer. Previously, Mr. Seto was responsible for overseeing the financial and operational management of the Company including, finance, accounting, treasury and capital markets, as well as corporate planning and development, and investor relations. Prior to joining Spectral Medical, Mr. Seto was the CFO of MJardin Group Inc. (CSE:MJAR) and GrowForce Holdings Inc. Mr. Seto has over 25 years of capital markets and financial management experience, including senior investment banking positions with Paradigm Capital, UBS Securities and CIBC World Markets; and financial management experience in the telecom and healthcare industries with Bell Canada and Warren Shepell. Mr. Seto holds a B. Comm. from McMaster University, an MBA from the Richard Ivey School of Business, and a Certified Management Accountant designation (C.M.A. 1999). “I would like to thank Dr. Walker and the Board of Directors for their confidence in my ability to lead Spectral to achieve growth in product commercialization, revenues and earnings in due course. I look forward to working with the Spectral team to continue on the exciting path we have developed for our Company under the leadership of Dr. Walker,” said Chris Seto, COO and CFO of Spectral Medical. “Over the last year we refined our corporate structure, including the recent appointment of Dr. John Kellum as Chief Medical Officer, which will make this transition seamless while maintaining our team’s focus on achieving our key corporate priorities.” Dr. Walker commented, “I am very pleased that Chris is transitioning to the Chief Executive Officer position. Since joining the Company, Chris has demonstrated outstanding operational and financial leadership, and has played a key role in defining our strategy for the Dialco subsidiary. With the recent addition of Dr. John Kellum to our organization, I am confident that we are well positioned to successfully complete the Tigris Trial and to advance our scientific and product development agenda for Spectral.” Anthony Bihl, Chairman of Spectral, further noted, “Chris’ transition to CEO is a reflection of his unwavering commitment and outstanding leadership. Moreover, I would like to personally express our sincere gratitude to Dr. Paul Walker, who has successfully led the organization over the last twenty years through a transition from a diagnostic focused company to a leading theranostics company focused on bringing unique commercial products to market—positioning us for long-term success. As one of the world’s leading experts on endotoxin and its role in sepsis, as well as the co-inventor of the Endotoxin Activity Assay (EAA™), we look forward to his continued contributions as we advance the Tigris Trial.” About Spectral Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis. PMX is approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 200,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 330,000 patients are diagnosed with severe sepsis and septic shock in North America each year. Spectral, through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new proprietary platform, “SAMI”, targeting the renal replacement therapy (“RRT”) market. Dialco is also seeking regulatory approval for in-home use of “DIMI” which is based on the same RRT platform, but will be intended for home hemodialysis use. “DIMI” recently received its FDA 510k clearance for use in hospital and clinical settings. Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit www.spectraldx.com. Forward Looking StatementInformation in this news release that is not current or historical factual information may constitute forward-looking information or forward looking statements within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral’s senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities including but not limited to the ongoing impact of COVID-19. Actual results could differ materially from what is currently expected, and readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company disclaims any obligation to update or revise any forward-looking statements. Reference is also made to the other risks and uncertainties that may affect the Company which are more fully described in Spectral’s Annual Information Form dated March 26, 2020 and other filings of Spectral with the securities regulatory authorities which are available at www.sedar.com. The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. Contact: Mr. Chris SetoMr. Ali MahdaviDavid Waldman/Natalya RudmanCOO & CFOCapital Markets & InvestorUS Investor RelationsSpectral Medical Inc. RelationsCrescendo Communications, LLC416-626-3233 ext. 2004416-962-3300212-671-1020cseto@spectraldx.com am@spinnakercmi.com edt@crescendo-ir.com

  • GlobeNewswire

    MJardin Announces Standing Offer Agreement with Alberta Gaming, Liquor and Cannabis

    BLLRDR and Flint & Embers prepare to launch across AlbertaNOT FOR RELEASE OR DISSEMINATION INTO THE UNITED STATES TORONTO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- MJardin Group, Inc. (CSE: MJAR) (the “Company” or “MJardin”), a leader in premium cannabis production, today announced that it has been registered to sell cannabis through Alberta Gaming, Liquor and Cannabis (“AGLC”), and has entered into a standing offer agreement with AGLC for the sale of its premium high-quality cannabis in the Alberta market, under the Flint & Embers and BLLRDR brands. AGLC is responsible for regulating private retail cannabis, the distribution of cannabis and operation of Alberta's only legal online cannabis store, AlbertaCannabis.org. The AGLC registration and standing offer agreement enables MJardin to make its product available to consumers in Alberta, which is the fourth largest populous market with the second largest cannabis sales in Canada. With active agreements in place in Ontario, British Columbia and Alberta, the Company now services over two-thirds of the Canadian population and anticipates increased revenues as a direct result of their increased availability across Canada. Moving into the Alberta market marks a key step in the achievement of MJardin’s 2021 goals. Last year, the Company set forth on a path to develop knowledge and create processes required for successful brand launches in the emerging recreational cannabis market in Canada. Today, the Company displays laser focus on its Canadian consumer-facing brand, Flint & Embers, and partner brand, BLLRDR. “We have put a lot of time and effort into identifying our unique and unassailable competitive strengths before applying them elsewhere,” stated Pat Witcher, CEO of MJardin. “We have determined the nature of our strengths and we have identified our value in this new market. Our excellent horticultural background and data driven processes have radically improved the performance of our company over the last four years. We’re excited to introduce the culmination of our commitment, to our high-quality cannabis products, through the market entry of our consumer-facing brands.” Alberta, having established early market leadership with nearly half of the cannabis retail locations in the country, continues to see rising earnings driven mainly by a proliferation of stores. MJardin plans to help Alberta capture additional customers by establishing a strong presence in the province through collaborative retailer engagements, consequently decreasing illicit market purchases. “This agreement will enable us to deliver high quality cannabis to another great Canadian market under favourable terms,” stated Eric Gattoni, Senior VP Business Development of MJardin. “The market for quality cannabis in Alberta is growing at a remarkable pace, and thanks to this agreement, and our strategically planned collaborative retailer engagements, we have a scalable means to help meet this demand”. Initial purchase orders and shipments of the Flint & Embers and BLLRDR brands are expected to occur Q1 of 2021. About MJardin Group MJardin’s mission is to set the standard for successful ownership of assets in the cannabis industry. Our founders spent a decade refining cultivation methodology, collecting and implementing data driven standards and designing state\ of the art facilities. Today, MJardin owns multiple operations in Canada, supplying the market with premium products. We are committed to our Canadian First Nation joint ventures and all our strategic partnerships across the cannabis supply chain. MJardin is publicly listed on the CSE (MJAR) and headquartered in Toronto, Ontario and Denver, Colorado. The CSE has not in any way passed upon the merits of and has neither approved nor disapproved the contents of this news release. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. Forward-Looking Information This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as, may’, ‘will’, ‘should’, ‘could’, ‘would’, ‘expects’, ‘intends’, ‘plans’, ‘anticipates’, ‘believes’, ‘estimates’, ‘projects’, ‘predicts’, ‘potential’, ‘outlook’ or ‘continue’ or the negative of those forms or other comparable terms. Statements about, among other things, future developments in the business and operations of MJardin, contain forward-looking information. These statements should not be read as guarantees of future performance or results. The Company’s forward-looking information and forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information and forward-looking statements, including but not limited to: our ability to identify and pursue growth, financing and other strategic objectives, and the regulatory and economic environments in the jurisdictions we operate or intend to operate or invest in. Reference should also be made to the risks and uncertainties which are discussed in greater detail in the “Risk Factors” section of the Company’s Annual Management’s Discussion and Analysis filed on SEDAR and as described from time to time in documents filed by the Company with Canadian securities regulatory authorities. Readers are cautioned that the foregoing list of factors is not exhaustive. Although such statements are based on management’s reasonable assumptions at the date such statements are made, there can be no assurance that any proposed transactions will occur or that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward-looking information and forward-looking statements. Accordingly, readers should not place undue reliance on the forward-looking information and forward-looking statements. No assurances are given as to the future trading price or trading volumes of MJardin’s shares, nor as to the Company’s financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company’s forward-looking information and forward-looking statements contained herein, whether as a result of new information, any future event or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise. MJardin assumes no responsibility to update or revise forward-looking information and forward-looking statements to reflect new events or circumstances unless required by applicable law. Caution Regarding Cannabis Operations in the United States Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. Cannabis remains a Schedule I drug under the US Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute or possess cannabis in the United States. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable US federal money laundering legislation. While the approach to enforcement of such laws by the federal government in the United States has trended toward non-enforcement against individuals and businesses that comply with medical or adult-use cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve the Company of liability under US federal law, nor will it provide a defense to any federal proceeding which may be brought against the Company. The enforcement of federal laws in the United States is a significant risk to the business of the Company and any proceedings brought against the Company thereunder may adversely affect the Company’s operations and financial performance. Investor Contact Ali Mahdavi Director of Capital Markets & Investor Relationsali.mahdavi@mjardin.com +1.416.962.3300 Pat Witcher Chief Executive Officerpat.witcher@mjardin.com +1.720.613.4019 Media Contact Terra Kimery Director of Marketing & Brand terra.kimery@mjardin.com Related Links www.mjardin.com www.flintandembers.com www.bllrdrco.com